Laboratory

National Institutes of Health awards Children’s National Hospital $6.7M to build out additional lab space at the new Children’s National Research & Innovation Campus, preparing phase II

National Institutes of Health, Policy, Council of the District of Columbia, Partnership, Virginia Tech, Epilepsy, European Bank for induced pluripotent Stem Cells, Economy, Workforce, Doctor of Philosophy, Lists of diseases, Harwell Science and Innovation Campus, Environment, Georgetown University, Cerebral palsy, Genomics, CEO, Ward, Disability in Canada, Armed Forces Institute of Pathology, Cell, National Institute, Intellectual disability, Research, Health equity, NIH, George Washington University, Informatics, Laboratory, Walter Reed Army Medical Center, RIC, Howard University, Economic development, Autism, Johnson & Johnson, GLOBE, Pharmaceutical industry, Medicine
Wednesday, September 22, 2021 - 9:04pm

Washington D.C., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Childrens National Hospital today announced a $6.7 million award from the National Institute of Health (NIH) for the new Childrens National Research & Innovation Campus (RIC).

Key Points: 
  • Washington D.C., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Childrens National Hospital today announced a $6.7 million award from the National Institute of Health (NIH) for the new Childrens National Research & Innovation Campus (RIC).
  • The campus began opening in early 2021 and brings together Childrens National with top-tier research and innovation partners: Johnson & Johnson Innovation - JLABS @ Washington, DC and Virginia Tech.
  • They come together with a focus on driving discoveries and innovation that will save and improve the lives of children.
  • This NIH award is the latest confirmation that we are creating something very special at the Childrens National Research & Innovation Campus, said Kurt Newman, M.D.

Dr. Sarah Teichmann FmedCci FRS Joins Transition Bio as Scientific Co-Founder

Technology, Biotechnology, Nanotechnology, Health, Pharmaceutical, Oncology, Other Science, Research, Software, General Health, Genetics, Science, Data Management, Clinical Trials, Biophysics, Biochemical Society, Distinguished Fellow of the British Computer Society, Artificial intelligence, Research, Computational biology, Wellcome Sanger Institute, Harvard University, OC, EMBO, Medicine, Teichmann, Therapy, Health, Yusuf Hamied Department of Chemistry, Mallinckrodt, Map, Research fellow, Cavendish Laboratory, Physical chemistry, Academy of Medical Sciences (United Kingdom), Laboratory, Gold medal, Fellow, International Society, Biology, Drug design, Genomics, University, Royal Society, Company, EMBO Gold Medal, Disease, Technology, Algorithm, Science, FRCP, Applied physics, Royal, Churchill College, Cambridge, Drug discovery, Transition, Department, FRS, FRSC, Machine learning, Physics, Academy, Management, Pharmaceutical industry
Wednesday, September 22, 2021 - 9:30pm

Transition Bio, Inc., (the Company) announced today that Dr. Sarah Teichmann FmedSci FRS, has joined the Company as a Scientific Co-Founder.

Key Points: 
  • Transition Bio, Inc., (the Company) announced today that Dr. Sarah Teichmann FmedSci FRS, has joined the Company as a Scientific Co-Founder.
  • Dr. Samuel Cohen, a former research fellow in Biophysical Chemistry at the University of Cambridge and visiting fellow at Harvard University, is also a Founder of the Company.
  • Martin commented further, From a scientific leadership and breakthrough innovation standpoint, the combination of our scientific team of doctors Weitz, Knowles, Hyslop, and now Teichmann is as good as it could possibly get.
  • Transition Bio is developing one-of-a-kind technologies for biomolecular condensate analysis.

Elicio Therapeutics Presents Updated Preclinical Data at the 2021 Vaccines Summit Demonstrating that ELI-005, a Lymph Node Targeted Amphiphile Vaccine, Induces Potent Cellular and Humoral Immunity to SARS-CoV-2

B.1.1.7, Mouse, Therapy, Infection, Cancer, Koch Institute, Vaccine, Compliance, Biomedicine, Amplifier, MIT, Spike, Elicio Berriz, Immunity, FDA, Patient, Engineering, Development, Epitope, Koch Institute for Integrative Cancer Research, Immune system, Immunology, Biomedical engineering, Immunotherapy, Lymph, Disease, Vaccination, COVID-19, Antigen, Severe acute respiratory syndrome coronavirus 2, CpG, Darrell Irvin, RBD, Safety, KRAS, Laboratory, Massachusetts Institute of Technology, Forward-looking statement, AMP, Massachusetts, GLOBE, Pharmaceutical industry
Wednesday, September 22, 2021 - 8:22pm

We are encouraged by these positive results for ELI-005 demonstrating that delivery of AMP-CpG adjuvant to the lymph nodes induces both cellular and humoral responses to SARS-CoV-2 antigens.

Key Points: 
  • We are encouraged by these positive results for ELI-005 demonstrating that delivery of AMP-CpG adjuvant to the lymph nodes induces both cellular and humoral responses to SARS-CoV-2 antigens.
  • This dual response is critical in developing broad protective immunity in patients, said Peter DeMuth, Ph.D., vice president of research at Elicio Therapeutics.
  • We believe our AMP lymph node targeted approach will produce superior clinical benefits compared to immunotherapies that do not engage the lymph nodes.
  • Elicio is engineering lymph node targeted AMPlifiers, immunomodulators, adjuvants and vaccines for an array of aggressive cancers and infectious diseases.

Global Lab Automation Market Analysis Report 2021-2028: Advantages Offered by Lab Automation. Increasing Demand for Miniaturization, & Rise in Applications of Lab Automation - ResearchAndMarkets.com

Health, Biotechnology, Adoption, Infection, Fluid, DNA, Culture, Miniaturization, Growth, Prevalence, Risk, Automation, Synthetic biology, Process, Laboratory, Data collection, Fine chemical, Medical device, Video game
Wednesday, September 22, 2021 - 3:08pm

The "Global Lab Automation Market Size, Share & Trends Analysis Report by Process (Continuous Flow, Discrete Processing), by Automation Type (Total Automation Systems, Modular Automation Systems), by End Use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Lab Automation Market Size, Share & Trends Analysis Report by Process (Continuous Flow, Discrete Processing), by Automation Type (Total Automation Systems, Modular Automation Systems), by End Use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • Key drivers of the market include a rise in the gap between the availability of trained laboratory personnel and the demand for laboratory procedures and high reproducibility and accuracy obtained through lab automation.
  • The rise in applications of lab automation is one of the major factors anticipated to boost growth during the forecast period.
  • A rise in product launches undertaken by dominant players is anticipated to boost the market growth.

IV BioHoldings Debuts Liquid Biopsy Portfolio; Partners with P4 Diagnostix to Scale Commercialization of Non-Invasive Lung, Liver and Breast Diagnostics

Biotechnology, General Health, Other Health, Health, Oncology, Blood, Efficiency, Explainable artificial intelligence, Non-alcoholic fatty liver disease, Saliva, Entrepreneurship, EHR, Â, Pathology, Informatics, Laboratory, Liquid biopsy, Breast cancer, Industry, Classification, Lung, NAFL, Behavior, Health, IV, NAFLD, IP, NASH, CEO, Disease, Science, Technology, Lists of diseases, Fatty liver disease, Clinical trial, Partnership, Molecular medicine, Solution, Woman, Risk, Liver, Agnostic (data), R, Ecosystem, Intellectual property, Time, LBS, Degenerative disease, Diagnosis, CLIA, Patient, Biology, Lung cancer, Research, Drug development, Data analysis, Time-invariant system, Medical imaging, Fine chemical, Medical device
Wednesday, September 22, 2021 - 4:14pm

Collectively, the IVBH companies comprise eight clinical-ready diagnostics, spanning the care continuum for lung cancer, non-alcoholic fatty liver disease (NAFLD) and breast cancer, respectively.

Key Points: 
  • Collectively, the IVBH companies comprise eight clinical-ready diagnostics, spanning the care continuum for lung cancer, non-alcoholic fatty liver disease (NAFLD) and breast cancer, respectively.
  • IVBH is now scaling to support its flagship lung, liver and breast programs through clinical development and commercialization.
  • We are a bio innovation studio specializing in de novo company creation at the intersection of diagnostics and life sciences.
  • P4 is made up of these industry-leading companies: Theranostix, Long Island Pathology, Platinum Pathology, Metamark Laboratories and P4 Clinical.

Global Laboratory Equipment Services Market Procurement Intelligence Report with COVID-19 Impact Analysis | SpendEdge

CAGR, SLA, KPI, Laboratory, USD, Pressure, COVID-19, Sales, Renewable energy, Oil
Wednesday, September 22, 2021 - 2:37pm

This report also offers market impact and new opportunities created due to the COVID-19 pandemic.

Key Points: 
  • This report also offers market impact and new opportunities created due to the COVID-19 pandemic.
  • Insights into buyer strategies and tactical negotiation levers:
    Several strategic and tactical negotiation levers are explained in the report to help buyers achieve the best prices for the Laboratory Equipment Services market.
  • Some of the top Laboratory Equipment Services suppliers listed in this report:
    This Laboratory Equipment Services procurement intelligence report has enlisted the top suppliers and their cost structures, SLA terms, best selection criteria, and negotiation strategies.
  • To get instant access to over 1000 market-ready procurement intelligence reports without any additional costs or commitment.

Solid Power to Host and Stream “Solid-State of Affairs” Industry Expert Roundtable on October 8, 2021

Securities Act of 1933, CTO, Investissement Québec, Sports Properties Acquisition Corporation, University, Communication, Reading, Science, Cell, SEC, Research, Failure, Physical chemistry, Development, Ford Motor Company, Form, CEO, BMW, Technology, University of California, San Diego, Prospectus, Energy, Lithium, University of Michigan, Sale, NASDAQ, Securities and Exchange Commission (Philippines), KIT, Acquisition, Risk, Conversion, Register, Mechanical engineering, SEC filing, McGill University, Name, GLOBE, Materials science, Temperature, Suite, Security (finance), LFP, Energy storage, Laboratory, Registration statement, Bloomberg L.P., BMW Group Plant Dingolfing, Nanoengineering, University of Giessen, Engineering, Securities Exchange Act of 1934, Electric battery, Cryptocurrency
Wednesday, September 22, 2021 - 2:00pm

In May 2021, Ford and the BMW Group expanded existing joint development agreements with Solid Power to secure all-solid-state batteries for future electric vehicles.

Key Points: 
  • In May 2021, Ford and the BMW Group expanded existing joint development agreements with Solid Power to secure all-solid-state batteries for future electric vehicles.
  • This communication is being made in respect of the proposed transaction involving Decarbonization Plus Acquisition Corporation III (DCRC) and Solid Power, Inc. (Solid Power).
  • Solid Power is an industry-leading developer of all-solid-state rechargeable battery cells for electric vehicles and mobile power markets.
  • Solid Power replaces the flammable liquid electrolyte in a conventional lithium-ion battery with a proprietary sulfide-based solid electrolyte.

ProPhase Labs to Present at the Benzinga Healthcare Small Cap Conference

Dietary supplement, Goal, PCR, Failure, OTC, Risk, Conference, CLIA, Private Securities Litigation Reform Act, DNA, Patient, Prophase, Chromosome, Gene, Marketing, Environment, Saliva, COVID, Company, Genomics, COVID-19 testing, Acquisition, COVID-19, Severe acute respiratory syndrome coronavirus 2, Research, Polymerase chain reaction, Laboratory, TK, Nasdaq, Inherited disorders of trafficking, SEC, RSV, GLOBE, Convenience food, Vaccine
Wednesday, September 22, 2021 - 1:30pm

GARDEN CITY, NY, Sept. 22, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH), a diversified biotech and genomics company, announces today that Chairman and CEO Ted Karkus will present at the Benzinga Healthcare Small Cap Conference, which is being held virtually from September 29 30, 2021.

Key Points: 
  • GARDEN CITY, NY, Sept. 22, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH), a diversified biotech and genomics company, announces today that Chairman and CEO Ted Karkus will present at the Benzinga Healthcare Small Cap Conference, which is being held virtually from September 29 30, 2021.
  • ProPhase Precision Medicine, Inc., focuses on genomics testing technologies, a comprehensive method for analyzing entire genomes, including the genes and chromosomes in DNA.
  • ProPhase Global Healthcare, Inc. was formed to seek to expand the Companys SARS-CoV-2 (COVID-19) testing into other countries and to pursue additional healthcare-related initiatives.
  • ProPhase Labs has decades of experience researching, developing, manufacturing, distributing, marketing, and selling OTC consumer healthcare products and dietary supplements, including dietary supplements under the TK Supplements brand.

AI-powered Solutions to Create an Ecosystem of Connected Laboratories for Superior Collaborations and Efficiencies

Artificial intelligence, Efficiency, Frost & Sullivan, Solution, Thermo Fisher Scientific, Software, Frost, Big data, Defence Research and Development Laboratory, Senior, Risk, Fourth Industrial Revolution, Technology, Automation, Research, Industry, R, Safety, Laboratory, Senior Consultant, Ecosystem, Pharmacy, Renewable energy, Medical device
Wednesday, September 22, 2021 - 1:04pm

SAN ANTONIO, Sept. 22, 2021 /PRNewswire/ -- The pandemic affected laboratory output regarding staffing and supply chains. Reduced on-site personnel and the constant risk of consumable and equipment shortages are driving the need for automation, cross-training, and remote collaboration. Scientists, vendors, and other stakeholders demand a push toward the "Laboratory of the Future," which leverages technology to improve productivity and innovation.

Key Points: 
  • Reduced on-site personnel and the constant risk of consumable and equipment shortages are driving the need for automation, cross-training, and remote collaboration.
  • Scientists, vendors, and other stakeholders demand a push toward the "Laboratory of the Future," which leverages technology to improve productivity and innovation.
  • The article also highlights the role of artificial intelligence (AI) solutions to enable a smart laboratory ecosystem.
  • Form strategic partnerships and nurture collaborations with global laboratories to speed therapeutic development from hypothesis to final-stage clinical studies via digital connections.

AI-powered Solutions to Create an Ecosystem of Connected Laboratories for Superior Collaborations and Efficiencies

Artificial intelligence, Efficiency, Frost & Sullivan, Solution, Thermo Fisher Scientific, Software, Frost, Big data, Defence Research and Development Laboratory, Senior, Risk, Fourth Industrial Revolution, Technology, Automation, Research, Industry, R, Safety, Laboratory, Senior Consultant, Ecosystem, Pharmacy, Renewable energy, Medical device
Wednesday, September 22, 2021 - 1:04pm

SAN ANTONIO, Sept. 22, 2021 /PRNewswire/ -- The pandemic affected laboratory output regarding staffing and supply chains. Reduced on-site personnel and the constant risk of consumable and equipment shortages are driving the need for automation, cross-training, and remote collaboration. Scientists, vendors, and other stakeholders demand a push toward the "Laboratory of the Future," which leverages technology to improve productivity and innovation.

Key Points: 
  • Reduced on-site personnel and the constant risk of consumable and equipment shortages are driving the need for automation, cross-training, and remote collaboration.
  • Scientists, vendors, and other stakeholders demand a push toward the "Laboratory of the Future," which leverages technology to improve productivity and innovation.
  • The article also highlights the role of artificial intelligence (AI) solutions to enable a smart laboratory ecosystem.
  • Form strategic partnerships and nurture collaborations with global laboratories to speed therapeutic development from hypothesis to final-stage clinical studies via digital connections.